We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
- Authors
Valanparambil, Rajesh M.; Lai, Lilin; Johns, Margaret A.; Davis-Gardner, Meredith; Linderman, Susanne L.; McPherson, Tarrant Oliver; Chang, Andres; Akhtar, Akil; Gamarra, Estefany L. Bocangel; Matia, Hayley; McCook-Veal, Ashley A.; Switchenko, Jeffrey; Nasti, Tahseen H.; Green, Felicia; Saini, Manpreet; Wieland, Andreas; Pinsky, Benjamin A.; Solis, Daniel; Dhodapkar, Madhav V.; Carlisle, Jennifer
- Abstract
This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4–6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.
- Subjects
BOOSTER vaccines; SARS-CoV-2 Omicron variant; LUNG cancer; CANCER patients; NON-small-cell lung carcinoma
- Publication
NPJ Vaccines, 2023, Vol 8, Issue 1, p1
- ISSN
2059-0105
- Publication type
Article
- DOI
10.1038/s41541-023-00779-8